{"DataElement":{"publicId":"3153607","version":"1","preferredName":"Patient Temsirolimus Lower Medication Eligibility Determination Ind-2","preferredDefinition":"the yes/no indicator related to criteria to determine eligibility of patients for medical care programs and services based on medication that decreases levels of an ester analog of rapamycin.","longName":"3153606v1.0:2018257v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3153606","version":"1","preferredName":"Patient Temsirolimus Lower Medication Eligibility Determination","preferredDefinition":"information related to criteria to determine eligibility of patients for medical care programs and services based on medication that decreases levels of an ester analog of rapamycin.","longName":"2233604v1.0:3153604v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3153604","version":"1","preferredName":"Temsirolimus Lower Medication Eligibility Determination","preferredDefinition":"An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.:To become lower, grow less, or diminish, as in amount, intensity, degree, or value.:biologically active substance, including those intended for use in diagnosis, treatment, or prevention of disease or other abnormalities, for the relief of suffering, or control or improvement of a physical or mental state; includes biological products.:Criteria to determine eligibility of patients for medical care programs and services.","longName":"C1844:C86568:C459:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temsirolimus","conceptCode":"C1844","definition":"An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Lower","conceptCode":"C86568","definition":"To become lower, grow less, or diminish, as in amount, intensity, degree, or value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93B0B207-32FC-B370-E040-BB89AD431C0F","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-10-28","modifiedBy":"ONEDATA","dateModified":"2010-10-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"93B0B207-330D-B370-E040-BB89AD431C0F","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-10-28","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"10000346","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"10000345","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"4104907","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"4104940","version":"1","longName":"GOG-0268","context":"NRG"}]}],"AlternateNames":[{"name":"3153606v1.0:2018257v1.0","type":"USED_BY","context":"NRG"},{"name":"RCV_DG_CYP3A4_IND","type":"COG GDE Short Name","context":"COG"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Is the patient receiving enzy","type":"Preferred Question Text","description":"Is the patient receiving enzyme-inducing antiepileptic drugs (EIAEDs; e.g., phenytoin, carbamazepine, phenobarbital) or any other CYP3A4 inducer such as rifampin or St. John's Wort, as these may decrease temsirolimus levels?","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Use of the following Enzyme Inducing Anti-Convulsive (EIAC) medications is prohibited <=7 days prior to registration: carbemazepine (Tegretol, Tegretol XR, Carbatrol), phenytoin (Dilantin, Phenytek), fosphenytoin (Cerebyx), phenobarbital, pentobarbital and primidone (Mysoline)","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Receiving enzyme-inducing antiepileptic drugs (EIACs; e.g., phenytoin, fosphenytoin, carbamazepine, phenobarbital, or primidone) or any other potent CYP3A4 inducer/inhibitor such as rifampin or St. John's wort","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Does the patient require chronic concomitant treatment of strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's Wort)?","url":null,"context":"CTEP"},{"name":"CRF Text 3","type":"Alternate Question Text","description":"Does the patient have concomitant use of known potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin, and nelfinavir","url":null,"context":"CTEP"},{"name":"CRF Text 5","type":"Alternate Question Text","description":"Is the patient using any strong CYP3A inducers (e.g., phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort)?","url":null,"context":"CTEP"},{"name":"COG CRF Text 01","type":"Alternate Question Text","description":"Did patient receive drugs that are strong inducers or inhibitors of CYP3A4 within 7 days prior to study enrollment?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Is the patient using any potent inhibitors or inducers of CYP3A4 within 2 weeks prior to the anticipated start date of study treatment, or within 3 weeks prior to the anticipated start date of study treatment if using St John's wort?","url":null,"context":"NRG"}],"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"93B0B207-331F-B370-E040-BB89AD431C0F","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-10-28","modifiedBy":"ZHWENDY","dateModified":"2022-07-20","changeDescription":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"7/202022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"}}